Evolent Health Inc (NYSE:EVH) has received a consensus rating of “Buy” from the ten analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $14.31.
Several research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Evolent Health from a “hold” rating to a “sell” rating in a research report on Wednesday, January 15th. SunTrust Banks reiterated a “buy” rating and set a $14.00 price objective on shares of Evolent Health in a research report on Wednesday, December 4th. Wells Fargo & Co lowered their price objective on shares of Evolent Health from $19.00 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. KeyCorp lowered their price objective on shares of Evolent Health from $20.00 to $10.00 and set an “overweight” rating on the stock in a research report on Monday, December 2nd. They noted that the move was a valuation call. Finally, ValuEngine upgraded shares of Evolent Health from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd.
Shares of EVH stock traded down $0.44 during trading hours on Wednesday, hitting $10.50. 1,134,239 shares of the company were exchanged, compared to its average volume of 1,471,285. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.19 and a current ratio of 1.19. Evolent Health has a one year low of $5.50 and a one year high of $18.20. The business’s 50-day simple moving average is $9.13 and its two-hundred day simple moving average is $7.95. The stock has a market capitalization of $925.62 million, a price-to-earnings ratio of -7.09 and a beta of 1.11.
Evolent Health (NYSE:EVH) last issued its earnings results on Tuesday, November 5th. The technology company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.03. The firm had revenue of $220.14 million for the quarter, compared to analysts’ expectations of $217.90 million. Evolent Health had a negative net margin of 15.02% and a negative return on equity of 6.93%. Evolent Health’s revenue was up 46.8% on a year-over-year basis. During the same quarter last year, the company posted ($0.04) earnings per share. As a group, analysts anticipate that Evolent Health will post -0.95 EPS for the current fiscal year.
In related news, President Seth Blackley bought 14,749 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was bought at an average price of $6.68 per share, with a total value of $98,523.32. Insiders own 4.50% of the company’s stock.
Large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC acquired a new stake in shares of Evolent Health during the 3rd quarter valued at $129,000. GABELLI & Co INVESTMENT ADVISERS INC. boosted its stake in shares of Evolent Health by 20.6% during the 3rd quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 18,700 shares of the technology company’s stock valued at $134,000 after buying an additional 3,200 shares during the period. Voya Financial Advisors Inc. boosted its stake in shares of Evolent Health by 10.1% during the 3rd quarter. Voya Financial Advisors Inc. now owns 19,421 shares of the technology company’s stock valued at $141,000 after buying an additional 1,789 shares during the period. Metropolitan Life Insurance Co NY boosted its stake in shares of Evolent Health by 7.3% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 22,380 shares of the technology company’s stock valued at $161,000 after buying an additional 1,521 shares during the period. Finally, Walleye Trading LLC acquired a new stake in shares of Evolent Health during the 2nd quarter valued at $187,000. 98.34% of the stock is owned by institutional investors.
About Evolent Health
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Further Reading: What is FinTech?
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.